PMC · DOI:10.3389/fonc.2026.1803208·March 11, 2026
Challenges in employing overall survival as a primary outcome in ovarian cancer studies: insights from PARP inhibitor trials
Yoav Siegler, Emad Matanes
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPARP inhibition in cancer therapy · Ovarian cancer diagnosis and treatment · BRCA gene mutations in cancer